Correlation of glypican-1 expression with TGF-β, BMP, and activin receptors in pancreatic ductal adenocarcinoma

International Journal of Oncology

Volumn 29, Issue 5, 2006, Pages 1139-1148

  Kayed, Hany ^a   Kleeff, Jörg ^a   Keleg, Shereen ^a   Jiang, Xiaohua ^a   Penzel, Roland ^a   Giese, Thomas ^a   Zentgraf, Hanswalter ^b   Büchler, Markus W ^a   Korc, Murray ^c   Friess, Helmut ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Activin; Bone morphogenic protein; Glypican; Heparan sulfate proteoglycans; TGF 1

Indexed keywords

ACTIVIN RECEPTOR; BONE MORPHOGENETIC PROTEIN RECEPTOR; GLYPICAN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA;

ADULT; AGED; ARTICLE; CANCER STAGING; DOWN REGULATION; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PANCREAS CARCINOMA; PANCREAS TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION;

ACTIVIN RECEPTORS; ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN RECEPTORS; CARCINOMA, PANCREATIC DUCTAL; DOWN-REGULATION; FEMALE; GLYPICANS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PANCREATIC NEOPLASMS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 34548822519     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.29.5.1139     Document Type: Article

References (49)

1. Nakato H, Futch TA and Selleck SB: The division abnormally delayed (dally) gene: a putative integral membrane proteoglycan required for cell division patterning during postembryonic development of the nervous system in Drosophila. Development 121: 3687-3702, 1995.
2. Filmus J and Selleck SB: Glypicans: proteoglycans with a surprise. J Clin Invest 108: 497-501, 2001.
3. Higashiyama S, Abraham JA and Klagsbrun M: Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol 122: 933-940, 1993.
4. Mizuno K, Inoue H, Hagiya M, Shimizu S, Nose T, Shimohigashi Y and Nakamura T: Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor. J Biol Chem 269: 1131-1136, 1994.
5. Dougher AM, Wasserstrom H, Torley L, Shridaran L, Westdock P, Hileman RE, Fromm JR, Anderberg R, Lyman S, Linhardt RJ, Kaplan J and Terman BI: Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. Growth Factors 14: 257-268, 1997.
6. Reichsman F, Smith L and Cumberledge S: Glycosaminoglycans can modulate extracellular localization of the wingless protein and promote signal transduction. J Cell Biol 135: 819-827, 1996.
7. Segarini PR and Seyedin SM: The high molecular weight receptor to transforming growth factor-beta contains glycosaminoglycan chains. J Biol Chem 263: 8366-8370, 1988.
8. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC and Saunders S: Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 225: 179-187, 2000.
9. Nakamura T, Sugino K, Titani K and Sugino H: Follistatin, an activin-binding protein, associates with heparan sulfate chains of proteoglycans on follicular granulosa cells. J Biol Chem 266: 19432-19437, 1991.
10. Romaris M, Bassols A and David G: Effect of transforming growth factor-beta 1 and basic fibroblast growth factor on the expression of cell surface proteoglycans in human lung fibroblasts. Enhanced glycanation and fibronectin-binding of CD44 proteoglycan, and down-regulation of glypican. Biochem J 310: 73-81, 1995.
11. Elenius K, Maatta A, Salmivirta M and Jalkanen M: Growth factors induce 3T3 cells to express bFGF-binding syndecan. J Biol Chem 267: 6435-6441, 1992.
12. Cizmeci-Smith G, Stahl RC, Showalter LJ and Carey DJ: Differential expression of transmembrane proteoglycans in vascular smooth muscle cells. J Biol Chem 268: 18740-18747, 1993.
13. Derynck R, Goeddel DV, Ullrich A, Gutterman JU, Williams RD, Bringman TS and Berger WH: Synthesis of messenger RNAs for transforming growth factors alpha and beta and the epidermal growth factor receptor by human tumors. Cancer Res 47: 707-712, 1987.
14. Dickson RB, Kasid A, Huff KK, Bates SE, Knabbe C, Bronzert D, Gelmann EP and Lippman ME: Activation of growth factor secretion in tumorigenic states of breast cancer induced by 17 beta-estradiol or v-Ha-ras oncogene. Proc Natl Acad Sci USA 84: 837-841, 1987.
15. Massague J, Blain SW and Lo RS: TGFbeta signaling in growth control, cancer, and heritable disorders. Cell 103: 295-309, 2000.
16. De Caestecker MP, Piek E and Roberts AB: Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 92: 1388-1402, 2000.
17. Lagna G, Hata A, Hemmati-Brivanlou A and Massague J: Partnership between DPC4 and SMAD proteins in TGF-beta signalling pathways. Nature 383: 832-836, 1996.
18. Derynck R and Feng XH: TGF-beta receptor signaling. Biochim Biophys Acta 1333: F105-F150, 1997.
19. Piek E, Heldin CH and Ten Dijke P: Specificity, diversity, and regulation in TGF-beta superfamily signaling. FASEB J 13: 2105-2124, 1999.
20. Itoh S, Itoh F, Goumans MJ and Ten Dijke P: Signaling of transforming growth factor-beta family members through Smad proteins. Eur J Biochem 267: 6954-6967, 2000.
21. Miyazono K, ten Dijke P and Heldin CH: TGF-beta signaling by Smad proteins. Adv Immunol 75: 115-157, 2000.
22. Kleeff J, Ishiwata T, Friess H, Buchler MW and Korc M: Concomitant over-expression of activin/inhibin beta subunits and their receptors in human pancreatic cancer. Int J Cancer 77: 860-868, 1998.
23. Kleeff J, Maruyama H, Ishiwata T, Sawhney H, Friess H, Buchler MW and Korc M: Bone morphogenetic protein 2 exerts diverse effects on cell growth in vitro and is expressed in human pancreatic cancer in vivo. Gastroenterology 116: 1202-1216, 1999.
24. Wagner M, Kleeff J, Friess H, Buchler MW and Korc M: Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19: 370-376, 1999.
25. Beauchamp RD, Lyons RM, Yang EY, Coffey RJ Jr and Moses HL: Expression of and response to growth regulatory peptides by two human pancreatic carcinoma cell lines. Pancreas 5: 369-380, 1990.
26. Friess H, Yamanaka Y, Buchler M, Berger HG, Kobrin MS, Baldwin RL and Korc M: Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 53: 2704-2707, 1993.
27. Friess H, Yamanaka Y, Buchler M, Ebert M, Beger HG, Gold LI and Korc M: Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105: 1846-1856, 1993.
28. Lu Z, Friess H, Graber HU, Guo X, Schilling M, Zimmermann A, Korc M and Buchler MW: Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 42: 2054-2063, 1997.
29. Hahn SA, Schutte M, Hoque AT, Moskaluk CA, Da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH and Kern SE: DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271: 350-353, 1996.
30. Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Buchler MW, Falb D and Korc M: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 18: 5363-5372, 1999.
31. Kleeff J, Maruyama H, Friess H, Buchler MW, Falb D and Korc M: Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 255: 268-273, 1999.
32. Baldwin RL, Friess H, Yokoyama M, Lopez ME, Kobrin MS, Buchler MW and Korc M: Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 67: 283-288, 1996.
33. Venkatasubbarao K, Ahmed MM, Mohiuddin M, Swiderski C, Lee E, Gower WR Jr, Salhab KF, McGrath P, Strodel W and Freeman JW: Differential expression of transforming growth factor beta receptors in human pancreatic adenocarcinoma. Anticancer Res 20: 43-51, 2000.
34. Kleeff J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD and Korc M: The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102: 1662-1673, 1998.
35. Kleeff J, Wildi S, Kumbasar A, Friess H, Lander AD and Korc M: Stable transfection of a glypican-1 antisense construct decreases tumorigenicity in PANC-1 pancreatic carcinoma cells. Pancreas 19: 281-288, 1999.
36. Li J, Kleeff J, Kayed H, Felix K, Penzel R, Buchler MW, Korc M and Friess H: Glypican-1 antisense transfection modulates TGF-beta-dependent signaling in Colo-357 pancreatic cancer cells. Biochem Biophys Res Commun 320: 1148-1155, 2004.
37. Guo J, Kleeff J, Li J, Ding J, Hammer J, Zhao Y, Giese T, Korc M, Buchler MW and Friess H: Expression and functional significance of CDC25B in human pancreatic ductal adenocarcinoma. Oncogene 23: 71-81, 2004.
38. Kayed H, Kleeff J, Keleg S, Buchler MW and Friess H: Distribution of Indian hedgehog and its receptors patched and smoothened in human chronic pancreatitis. J Endocrinol 178: 467-478, 2003.
39. Köhler G and Milstein C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495-497, 1975.
40. Kayed H, Kleeff J, Kolb A, Ketterer K, Keleg S, Felix K, Giese T, Penzel R, Zentgraf H, Buchler MW, Korc M and Friess H: FXYD3 is overexpressed in pancreatic ductal adenocarcinoma and influences pancreatic cancer cell growth. Int J Cancer 118: 43-54, 2006.
41. Jackson SM, Nakato H, Sugiura M, Jannuzi A, Oakes R, Kaluza V, Golden C and Selleck SB: Dally, a Drosophila glypican, controls cellular responses to the TGF-beta-related morphogen, Dpp. Development 124: 4113-4120, 1997.
42. Lin X and Perrimon N: Role of heparan sulfate proteoglycans in cell-cell signaling in Drosophila. Matrix Biol 19: 303-307, 2000.
43. Matsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD and Korc M: Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res 61: 5562-5569, 2001.
44. Davies EJ, Blackhall FH, Shanks JH, David G, McGown AT, Swindell R, Slade RJ, Martin-Hirsch P, Gallagher JT and Jayson GC: Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin Cancer Res 10: 5178-5186, 2004.
45. Qiao D, Meyer K, Mundhenke C, Drew SA and Friedl A: Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. Specific role for glypican-1 in glioma angiogenesis. J Biol Chem 278: 16045-16053, 2003.
46. Zhu ZW, Friess H, Wang L, Abou-Shady M, Zimmermann A, Lander AD, Korc M, Kleeff J and Buchler MW: Enhanced glypican-3 expression differentiates the majority of hepatocellular carcinomas from benign hepatic disorders. Gut 48: 558-564, 2001.
47. Zhu Z, Friess H, Kleeff J, Wang L, Wirtz M, Zimmermann A, Korc M and Buchler MW: Glypican-3 expression is markedly decreased in human gastric cancer but not in esophageal cancer. Am J Surg 184: 78-83, 2002.
48. Nakatsura T, Kageshita T, Ito S, Wakamatsu K, Monji M, Ikuta Y, Senju S, Ono T and Nishimura Y: Identification of glypican-3 as a novel tumor marker for melanoma. Clin Cancer Res 10: 6612-6621, 2004.
49. Grisaru S, Cano-Gauci D, Tee J, Filmus J and Rosenblum ND: Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol 231: 31-46, 2001.